I would like to see CYDY license out the cancer indications, and with that boatload of money, explore leronlimab in a wide range of inflammatory, infectious and neurological diseases. Alzheimers, MS, Parkinsons... Fibrotic indications. Atherosclerosis. Sepsis. Autoimmune diseases. Etc...
As the company that killed metastatic cancer, Cytodyn will have a great deal of goodwill from the public. So I would hate to see the company just disappear from the earth as the developmental process plays out. Pick an indication, or organ or area of interest, and license out the rest. Perhaps the company will focus on unlocking the potential of long-acting leronlimab. And--can you say Contingent Value Rights for these future indications? Perhaps the prospect of substantial dividends or other disbursements as the indications continue to evolve and grow with time and trials?
Speaking of trials--the one I'd like to see is leronlimab vs semaglutide, head-to-head, with years of life/death as the primary endpoint. And lots of relevant secondary endpoints like deaths from cancer, heart disease, incidence of Alzheimers... Say a 20 year timeline to really see if either of these drugs work against some of the more common ailments that plague humanity... and extend life and quality of life. Such a trial probably won't happen, unless the NIH gets on it. But it would be incredibly fascinating for the healing professions.
As the company that killed metastatic cancer, Cytodyn will have a great deal of goodwill from the public. So I would hate to see the company just disappear from the earth as the developmental process plays out. Pick an indication, or organ or area of interest, and license out the rest. Perhaps the company will focus on unlocking the potential of long-acting leronlimab. And--can you say Contingent Value Rights for these future indications? Perhaps the prospect of substantial dividends or other disbursements as the indications continue to evolve and grow with time and trials?
Speaking of trials--the one I'd like to see is leronlimab vs semaglutide, head-to-head, with years of life/death as the primary endpoint. And lots of relevant secondary endpoints like deaths from cancer, heart disease, incidence of Alzheimers... Say a 20 year timeline to really see if either of these drugs work against some of the more common ailments that plague humanity... and extend life and quality of life. Such a trial probably won't happen, unless the NIH gets on it. But it would be incredibly fascinating for the healing professions.
4
